Conjugate Or Complex Includes Bacterium Or Component Thereof Or Substance Produced By Said Bacterium Patents (Class 424/197.11)
-
Patent number: 7534442Abstract: The present invention is directed to immunogenic conjugates comprised of a polymer, preferably a polysaccharide, with a covalently attached antigen and an agent for boosting a patient's immune response. The conjugates may be used in vaccines for a wide range of diseases.Type: GrantFiled: August 20, 2002Date of Patent: May 19, 2009Assignee: The Brigham and Women's Hospital, Inc.Inventor: Lawrence C. Paoletti
-
Patent number: 7531179Abstract: The present invention provides BoNT/A peptides as well as methods of predicting or determining immunoresistance to botulinum toxin therapy in an individual using BoNT/A peptides.Type: GrantFiled: March 29, 2007Date of Patent: May 12, 2009Assignee: Allergan, Inc.Inventor: M. Zouhair Atassi
-
Publication number: 20090117147Abstract: The present invention relates to the field of vaccine formulation, particularly the field of novel adjuvant compositions comprising outer membrane vesicles (or blebs), and advantageous methods of detoxifying these compositions, and advantageous methods of use of such adjuvants.Type: ApplicationFiled: December 3, 2007Publication date: May 7, 2009Inventors: Francois-Xavier Jacques BERTHET, Wilfried L J. Dalemans, Philippe Denoel, Guy Dequesne, Christiane Feron, Nathalie Garcon, Yves Lobet, Jan Poolman, Georges Thiry, Joelle Thonnard, Pierre Voet
-
Publication number: 20090117148Abstract: Precipitated bacterial capsular polysaccharides can be efficiently re-solubilised using alcohols as solvents. The invention provides a process for purifying a bacterial capsular polysaccharide, comprising the steps of (a) precipitation of said polysaccharide, followed by (b) solubilisation of the precipitated polysaccharide using ethanol. CTAB can be used for step (a). The material obtained, preferably following hydrolysis and sizing, can be conjugated to a carrier protein and formulated as a vaccine. Also, in vaccines comprising saccharides from both serogroups A and C, the invention provides that the ratio (w/w) of MenA saccharide:MenC saccharide is >1.Type: ApplicationFiled: January 9, 2009Publication date: May 7, 2009Applicant: Corporate Intellectual Property R338Inventor: Paolo Costantino
-
Patent number: 7524509Abstract: An adjuvant complex composed of bacterial outer membrane protein proteosomes complexed to bacterial liposaccharide is prepared to contain the component parts under a variety of conditions. The complex can be formulated with antigenic material to form immunogenic compositions, vaccines and immunotherapeutics. An induced immune response includes protective antibodies and/or type 1 cytokines is shown for a variety of protocols.Type: GrantFiled: March 11, 2002Date of Patent: April 28, 2009Assignee: ID Biomedical Corporation of QuebecInventors: David S. Burt, George H. Lowell, Gregory L. White, David Jones, Clement Rioux
-
Publication number: 20090098156Abstract: Multivalent meningococcal conjugate vaccines are administered according to a schedule in which at least one or two doses are administered to a patient aged between 0 and 12 months, and a further dose is administered to a patient aged between 12 and 24 months.Type: ApplicationFiled: October 6, 2008Publication date: April 16, 2009Inventor: Lisa Danzig
-
Patent number: 7510717Abstract: A method is provided for identifying, isolating, and producing htrB mutants of gram-negative bacterial pathogens. The method comprises mutating the htrB gene of a gram-negative bacterial pathogen so that there is a lack of a functional htrB protein, resulting in a mutant that lacks one or more secondary acyl chains contained in the wild type gram-negative bacterial pathogen, and displays substantially reduced toxicity as compared to the wild type strain. Also, the present invention provides methods for using a vaccine formulation containing the htrB mutant, the endotoxin isolated therefrom, or the endotoxin isolated therefrom which is then conjugated to a carrier protein, to immunize an individual against infections caused by gram-negative bacterial pathogens by administering a prophylactically effective amount of the vaccine formulation.Type: GrantFiled: January 12, 2006Date of Patent: March 31, 2009Assignee: University of Iowa Research FoundationInventors: Michael A. Apicella, Melvin G. Sunshine, Na-Gyong Lee, Rasappa Arumugham, Bradford W. Gibson
-
Publication number: 20090068220Abstract: The present invention relates to methods and compositions for treating urinary tract infections. In particular, the present invention relates to vaccines and immune modulators for treating urinary tract infections.Type: ApplicationFiled: September 5, 2008Publication date: March 12, 2009Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGANInventor: Harry L. T. Mobley
-
Patent number: 7501125Abstract: The present invention relates to a method of inducing a CD8+ CTL response to a molecule in an individual deficient in CD4+ T cells comprising administering to the individual an hsp or a portion of an ATP binding domain of an hsp joined to the molecule. In one embodiment, the present invention relates to a method of treating HIV in an individual deficient in CD4+ T cells comprising administering to the individual an hsp or a portion of an ATP binding domain of an hsp joined to the molecule. Also encompassed by the present invention is a method of inducing a CD4+ independent CTL response in an individual comprising administering to the individual a portion of an ATP binding domain of an hsp joined to the molecule. The present invention also relates to a method of inducing a CD8+ CTL response in an individual comprising administering to the individual a portion of an ATP binding domain of an hsp joined to the molecule.Type: GrantFiled: July 1, 2004Date of Patent: March 10, 2009Assignees: Whitehead Institute for Biomedical Research, Massachusetts Institute of TechnologyInventors: Qian Huang, Joan F. L. Richmond, Bryan K. Cho, Deborah Pallister, Jianzhu Chen, Herman N. Eisen, Richard A. Young
-
Publication number: 20090060945Abstract: Conjugated meningococcal capsular saccharides will be introduced into immunisation schedules in the near future, but the phenomenon of “carrier suppression” must first be addressed, particularly where multiple conjugates are to be used. It has been found that diphtheria toxoid and its derivatives (such as CRM197) can safely be used as the carrier protein, even where multiple meningococcal conjugates are administered at the same time and where a patient has previously been exposed to the carrier protein, either in the form of a previous immunogen (e.g. in a DTP vaccine) or as a previous carrier protein (e.g. in a Hib or pneumococcal conjugate vaccine). The invention provides a method for immunising a patient, comprising administering multiple conjugates of meningococcal capsular saccharides, wherein each conjugate comprises a diphtheria toxoid (or derivative thereof) carrier protein, and the capsular saccharide, and wherein the patient has been pre-immunised with a diphtheria toxoid (or derivative thereof).Type: ApplicationFiled: April 29, 2005Publication date: March 5, 2009Inventor: Cameron John Marshall
-
Publication number: 20090053248Abstract: The invention relates to fragments of Clostridium botulinum HC that can be linked with an entity (e.g., an antigen, a particle, or a radionuclide) and used to deliver the entity across a non-keratinized epithelial membrane of an animal. The fragments are useful, for example, for making vaccines, antidotes, and anti-toxins and in situations in which rapid uptake of an agent by an animal is desired.Type: ApplicationFiled: March 25, 2008Publication date: February 26, 2009Applicant: Thomas Jefferson UniversityInventors: Lance Simpson, Andrew Maksymowych, Jong-Beak Park
-
Patent number: 7494785Abstract: A method is provided of producing an immunogenic complex comprising a heat shock protein (hsp) coupled to a heterologous antigenic polypeptide, which method comprises: (a) expressing the antigenic polypeptide in a cell which cell has been subjected to a stimulus which causes the induction of a heat shock response in said cells; and (b) recovering the antigenic polypeptide coupled to one or more hsps from said cell or the culture medium. Also provided are immunogenic compositions comprising a heat shock protein (hsp) derived from a non-mammalian eukaryote coupled to a heterologous antigenic polypeptide which composition is capable of inducing an immune response to said antigenic polypeptide in a human or animal.Type: GrantFiled: August 18, 2000Date of Patent: February 24, 2009Assignee: Minister for Agriculture and Minister for Land and Water ConservationInventors: Anthony Douglas Shannon, Camilo Anthony Leo Selwyn Colaco, Melinda Jane Frost
-
Patent number: 7491404Abstract: The invention concerns an acellular immunogenic or vaccine composition for producing antibodies against Bacillus anthracis comprising a protective antigen (PA) and killed and optionally purified spores, obtained from mutating strains of Bacillus anthracis and their uses.Type: GrantFiled: September 15, 2005Date of Patent: February 17, 2009Assignees: Institut Pasteur, Centre National de la Recherche Scientifique-CNRSInventor: Michele Mock
-
Publication number: 20090041802Abstract: The present application discloses an immunogenic composition comprising N. meningitidis capsular polysaccharides from at least one of serogroups A, C, W135 and Y conjugated to a carrier protein to produce a N. meningitidis capsular polysaccharide conjugate, wherein the average size of each N. meningitidis polysaccharide is above 50 kDa.Type: ApplicationFiled: June 23, 2006Publication date: February 12, 2009Inventors: Ralph Leon Biemans, Dominique Boutriau, Carine Capiau, Philippe Denoel, Pierre Devivier, Jan Poolman
-
Publication number: 20090035326Abstract: Calcium phosphate is used as an adjuvant, with a high degree of antigen adsorption to the adjuvant. The invention is particularly useful for adjuvanting conjugated capsular saccharide antigens. Buffers, such as phosphate or histidine buffers, can advantageously be used in combination with the calcium phosphate, and compositions may have a pH in the range of 5.5 to 7.5.Type: ApplicationFiled: November 1, 2006Publication date: February 5, 2009Applicant: Novartis AGInventors: Mario Contorni, Manmohan Singh, Derek O'Hagan
-
Patent number: 7485321Abstract: Purified synthetic polypeptide ligands for targeting pharmaceutical agents and carriers comprising such agents to intestinal epithelial tissue, especially Peyer's patch and/or M-Cell tissue. Also methods of using the ligands.Type: GrantFiled: June 7, 2005Date of Patent: February 3, 2009Assignee: Merrion Research III LimitedInventors: Daniel J. O'Mahony, Imelda Lambkin, Lisa Higgins
-
Publication number: 20090017060Abstract: The invention relates to methods for making vaccines using linkages that are cleavable under lysosomal processing conditions, and vaccine compositions obtained therefrom. In some embodiments, the vaccines comprise a tumor antigen, an immunogenic carrier and a linker covalently linking the tumor antigen and the immunogenic carrier by a thio ether linkage. Vaccines of preferred embodiments can be used against a cellular proliferative disease that is characterized by the tumor antigen.Type: ApplicationFiled: March 9, 2007Publication date: January 15, 2009Inventor: John M. Timmerman
-
Publication number: 20090017059Abstract: The present invention discloses an immunogenic composition comprising S. pneumoniae capsular saccharide conjugates from serotypes 19A and 19F wherein 19A is conjugated to a first bacterial toxoid and 19F is conjugated to a second bacterial toxoid. Vaccines, methods of making vaccines and uses of the vaccines are also described.Type: ApplicationFiled: December 20, 2006Publication date: January 15, 2009Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.Inventors: Ralph Leon Biemans, Nathalie Marie-Josephe Garcon, Philippe Vincent Hermand, Jan Poolman, Marcelle Paulette Van Mechelen
-
Publication number: 20090017057Abstract: The present invention provides compositions and methods for stimulating an immune response using cationic lipids alone or in combination with antigens.Type: ApplicationFiled: March 17, 2008Publication date: January 15, 2009Applicant: PDS BIOTECHNOLOGY CORPORATIONInventors: Weihsu Chen, Weili Yan, Kenya Toney, Gregory Conn, Frank Bedu-Addo, Leaf Huang
-
Publication number: 20090010959Abstract: The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, a multivalent Streptococcus pneumoniae immunogenic composition is provided with various conjugated capsular saccharides from different S. pneumoniae serotypes conjugated to 2 or more different carrier proteins, where the composition comprises serotype 19F capsular saccharide conjugated to diphtheria toxoid (DT) or CRM197, optionally wherein 19F is the only saccharide in the composition conjugated to diphtheria toxoid (DT) or CRM197.Type: ApplicationFiled: December 20, 2006Publication date: January 8, 2009Inventors: Ralph Leon Biemans, Nathalie Marie-Josephe Garcon, Philippe Vincent Hermand, Jan Poolman, Marcelle Paulette Van Mechelen
-
Publication number: 20080317775Abstract: Novel enzymes, processes and antigenic structures useful in producing vaccines and compounds useful in combating gram-negative bacteria are described. Enzymes were isolated from the slime mould Dictyostelium discoideum and used to specifically degrade lipopolysaccharide (LPS). Enzymatic degradation permits residues of the LPS molecule, including immunogenic epitopes of the core oligosaccharide portion of the LPS, to remain unmodified during this enzymatic removal of fatty acids from the lipid A region of the LPS molecule.Type: ApplicationFiled: November 23, 2006Publication date: December 25, 2008Inventors: Andrew Cox, Dhamodharan Neelamegan, Ian Schoenhofen, Frank St. Michael, James Richards
-
Publication number: 20080305127Abstract: The invention provides vaccines against Neisseria meningitidis, pneumococcus and DTPa/w. In particular, it provides vaccines based on conjugated capsular saccharides from multiple meningococcal and/or pneumococcal serogroups. It further provides vaccine administration schemes for the immunisation of human patients with two or more of these vaccines.Type: ApplicationFiled: December 22, 2006Publication date: December 11, 2008Applicant: Glaxosmithkline Biologicals S.A.Inventor: Jan Poolman
-
Publication number: 20080299074Abstract: The present invention is directed to methods of producing conjugates of A? peptide immunogens with protein/polypeptide carrier molecules, which are useful as immunogens, wherein peptide immunogens are conjugated to protein carriers via activated functional groups on amino acid residues of the carrier or of the optionally attached linker molecule, and wherein any unconjugated reactive functional groups on amino acid residues are inactivated via capping, thus retaining the immunological functionality of the carrier molecule, but reducing the propensity for undesirable reactions that could render the conjugate less safe or effective. Furthermore, the invention also relates to such immunogenic products and immunogenic compositions containing such immunogenic products made by such methods.Type: ApplicationFiled: August 20, 2007Publication date: December 4, 2008Applicants: Elan Pharmaceuticals, Inc., WyethInventors: Rasappa G. Arumugham, A. Krishna Prasad
-
Publication number: 20080286300Abstract: The invention is based on methods that allow analysis of mixed meningococcal saccharides from multiple serogroups even though they share monosaccharide units. With a combination of saccharides from serogroups C, W135 and Y, the invention analyses sialic acid, glucose and galactose content. The glucose and galactose results are used to directly quantify saccharides from serogroups Y and W135, respectively, and the combined glucose and galactose content is subtracted from the sialic acid content to quantify saccharides from serogroup C. The three serogroups can thus be resolved even though their monosaccharide contents overlap. The three different monosaccharide analyses can be performed on the same material, without interference between the monosaccharides and without interference from any other saccharide materials in the composition (e.g. lyophilisation stabilisers).Type: ApplicationFiled: March 17, 2005Publication date: November 20, 2008Applicant: CHIRON SRLInventors: Angela Bardotti, Daniela Proietti, Stefano Ricci
-
Patent number: 7452982Abstract: The invention relates to an immunogenic complex comprising at a least one glycoside and at least one lipid, integrated into an iscom complex or matrix, and at least one antigen which antigen is integrated into the iscom complex or coupled on to or mixed with the iscom complex or iscom matrix complex, characterised in that it also comprises at least one enzyme. It also relates to such a complex further comprising at least one peptide which specifically binds to a receptor expressed on a cell capable of antigen presentation, which cell expresses MHC Class I or Class II and to compositions comprising the complexes.Type: GrantFiled: October 1, 2001Date of Patent: November 18, 2008Assignee: Arexis ABInventors: Nils Lycke, Kristian Dalsgaard, Allan Mc Mowat, Bjorn Lowenadler, Peter Kaastrup
-
Patent number: 7449189Abstract: Staphylococcal and Enterrococcal glycoconjugate vaccines are disclosed for use in preventing or treating bacterial infection in an immune-compromised individual. Such vaccines contain an immunocarrier and a conjugate of a polysaccharide or glycopeptide surface antigen from a clinically-significant bacterial strain. The vaccines can be used for active protection in immune-compromised individuals who are to be subjected to conditions that place them at immediate risk of developing a bacterial infection, as would be case in the context of a catheterization or a surgical procedure.Type: GrantFiled: January 25, 2006Date of Patent: November 11, 2008Assignee: NABI BiopharmaceuticalsInventors: Ali I. Fattom, Robert B. Naso
-
Publication number: 20080274135Abstract: The degree of polymerisation (DP) is an important parameter for analysis of saccharide antigens, particularly in glycoconjugates. The invention provides methods that can be used to measure DP for capsular saccharides, particularly for meningococcal saccharides e.g. from serogroups W135 and Y. A preferred method is based on reduction of terminal sialic acid residues on saccharides, with DP then being calculated by comparing the molar ratio of total sialic acid to reduced sialic acid.Type: ApplicationFiled: May 23, 2005Publication date: November 6, 2008Applicant: CHIRON SRLInventor: Angela Bardotti
-
Publication number: 20080260774Abstract: The present disclosure relates to synthetic alpha-galactosyl ceramide (?-GalCer) analogs, and their use as immunotherapies.Type: ApplicationFiled: April 14, 2008Publication date: October 23, 2008Inventors: Chi-Huey Wong, Alice Yu, Ya-Jen Chang
-
Publication number: 20080254058Abstract: The present invention pertains to a composition for the manufacture of a medicament comprising living or dead bacteria with controlled amounts of surface-coupled proteins or proteinaceous compounds and a method for the preparation of the composition. The bacterium provides a multivalent heterologous protein display vehicle that may be used in the manufacture of vaccines or medicaments for delivery via the mucosa.Type: ApplicationFiled: December 14, 2005Publication date: October 16, 2008Applicant: ALK-ABELLO A/SInventors: Jacob Glenting, Flemming Jorgensen, Soren Michael Madsen, Hans Israelsen
-
Publication number: 20080254057Abstract: Carrier-induced epitopic suppression is of particular concern where multiple conjugates with the same carrier protein are administered simultaneously. To avoid the suppression, the invention minimises the amount of unconjugated carrier protein in a vaccine. The invention provides a composition for immunising a patient against a disease caused by Neisseria meningitidis, wherein (1) the composition comprises conjugates for at least two of the four meningococcal serogroups A, C, W135 and Y, where at least two of the conjugates have a common carrier protein; and (2) the composition includes the common carrier in an unconjugated form at less than 10 ?g/ml.Type: ApplicationFiled: April 29, 2005Publication date: October 16, 2008Inventor: Paolo Costantino
-
Publication number: 20080254052Abstract: Specific genetic deletion are identified in mycobacteria isolates, including variations in the M. tuberculosis genome sequence between isolates, and numerous deletion present in BCG as compared to M. tb. These deletions are used as markers to distinguish between pathogenic and avirulent strains, and as a marker for particular M. tb isolates. Deletions specific to vaccine strains of BCG are useful in determining whether a positive tuberculin skin test is indicative of actual tuberculosis infection. The deleted sequences may be re-introduced into BCG to improve the efficacy of vaccination. Alternatively, the genetic sequence that corresponds to the deletion(s) are deleted from M. bovis or M. tubercuosis to attenuate the pathogenic bacteria.Type: ApplicationFiled: March 14, 2008Publication date: October 16, 2008Inventors: Marcel Behr, Peter Small, Gary Schoolnik, Michael A. Wilson
-
Publication number: 20080248059Abstract: GPC (gel permeation chromatography) and size exclusion chromatography with detection by multi-angle light scattering photometry (SEC-MALS) can be used to accurately measure molecular size and molar mass, respectively, of saccharide conjugates. The invention provides (a) a process for measuring the molecular size of a conjugated saccharide antigen within a sample, comprising a step of analyzing the sample by GPC, and (b) a process for measuring the molar mass of a conjugated saccharide antigen within a sample, comprising a step of analysing the sample by SEC-MALS.Type: ApplicationFiled: June 21, 2005Publication date: October 9, 2008Inventors: Giorgio Capannoli, Valeria Carinci, Sandro D'Ascenzi, Claudia Magagnoli
-
Publication number: 20080241180Abstract: Conjugated capsular saccharides from meningococcal serogroups C, W135 and Y are safe and immunogenic in humans when combined in a single dose. This effect is retained when a conjugated capsular saccharide from serogroup A is added. These conjugated antigens can be stably combined in a single aqueous dose without the need for lyophilisation. Broad protection against serogroup B infection can be achieved by using a small number of defined polypeptide antigens. These polypeptide antigens can be combined with the saccharide antigens without loss of protective efficacy for any of the five serogroups. Efficacy if retained even if a Hib conjugate is added. The efficacy of a serogroup W135 conjugate is enhanced by addition of protein antigens derived from a serogroup B strain. Addition of a Hib conjugate to meningococcal conjugates enhances the overall activity against meningococcus serogroup W135.Type: ApplicationFiled: October 4, 2004Publication date: October 2, 2008Inventor: Mario Contorni
-
Publication number: 20080241139Abstract: Adjuvant combinations comprising at least one microbial TLR agonist such as a whole virus, bacterium or yeast or portion thereof such a membrane, spheroplast, cytoplast, or ghost, a CD40 or 4-1BB agonist and optionally an antigen wherein all 3 moieties may be separate or comprise the same recombinant microorganism or virus are disclosed. The use of these immune adjuvants for treatment of various chronic diseases such as cancers and HIV infection is also provided.Type: ApplicationFiled: October 31, 2007Publication date: October 2, 2008Applicant: REGENTS OF THE UNIVERSITY OF COLORADOInventor: Dave DELUCIA
-
Publication number: 20080206276Abstract: Immunogenic compositions and methods for eliciting an immune response against S. epidermidis and other related staphylococci are provided. The immunogenic compositions can include immunogenic conjugates of poly-?-glutamic acid (such as ?DLPGA) polypeptides of S. epidermidis, or related staphylococci that express a ?PGA polypeptide. The ?PGA conjugates elicit an effective immune response against S. epidermidis, or other staphylococci, in subjects to which the conjugates are administered. A method of treating an infection caused by a Staphylococcus organism that expresses cap genes is also disclosed. The method can include selecting a subject who is at risk of or has been diagnosed with the infection by the Staphylococcus organism which expresses ?PGA from the cap genes. Further, the expression of a ?PGA polypeptide by the organism can then be altered.Type: ApplicationFiled: July 10, 2006Publication date: August 28, 2008Inventors: Michael Otto, Stanislava Kocianova
-
Publication number: 20080199490Abstract: The present application discloses an immunogenic composition comprising a Hib saccharide conjugate and at least two further bacterial saccharide conjugates wherein the Hib conjugate is present in a lower saccharide dose than the mean saccharide dose of all the at least two further bacterial saccharide conjugates.Type: ApplicationFiled: June 23, 2006Publication date: August 21, 2008Inventors: Ralph Leon Biemans, Dominique Boutriau, Carine Capiau, Philippe Denoel, Pierre Duvivier, Jan Poolman
-
Publication number: 20080193475Abstract: The present invention relates to a fermentation process comprising a fermentation step of growing a strain of Corynebacterium diphtheria in medium in a fermenter under conditions of agitation sufficient to maintain a homogenous culture and limited aeration such that pO2 within the culture falls to less than 4% for the majority of the fermentation step.Type: ApplicationFiled: March 21, 2006Publication date: August 14, 2008Inventors: Philippe Marc Helene Dehottay, Sandrine Dessoy, Olivier Marc Serge Ghislain Laloux, Marc Roger Fernand Orval
-
Publication number: 20080193476Abstract: The present application discloses an immunogenic composition comprising a Hib saccharide conjugate, at least one additional bacterial, for example N. meningitidis, saccharide conjugate(s), and a further antigen selected from the group consisting of whole cell pertussis and hepatitis B surface antigen, wherein the saccharide dose of the Hib saccharide conjugate is less than 5 ?g.Type: ApplicationFiled: June 23, 2006Publication date: August 14, 2008Inventors: Ralph Leon Biemans, Dominique Boutriau, Carine Capiau, Philippe Denoel, Pierre Duvivier, Jan Poolman
-
Patent number: 7408044Abstract: The invention relates to an adjuvant product which is intended to improve the activity of a molecule when administered to a host, characterized in that it comprises at least one part of the P40 protein of Klebsiella pneumoniae or a protein having at least 80% homology with the P40 protein of Klebsiella pneumoniae. The invention also relates to nucleotide sequences which encode these peptides or proteins and to the use of these sequences as a medicament. More particularly, such DNA sequences can be used in compositions which are intended for immunization by the intramuscular or intradermal route.Type: GrantFiled: April 1, 2004Date of Patent: August 5, 2008Assignee: Pierre Fabre MedicamentInventors: Hans Binz, Thierry Baussant, Jean-François Haeuw, Thien Ngoc Nguyen
-
Publication number: 20080160044Abstract: A method for preparing a protein-saccharide conjugate, comprising the steps of: (a) preparing an aqueous growth medium comprising soy peptone as a nitrogen source; (b) inoculating the medium with a Neisseria meningitidis bacterium; (c) incubating the medium to allow growth of the bacterium; (d) preparing capsular saccharide from the bacterium; and (e) conjugating the capsular saccharide to a carrier protein, to give the protein-saccharide conjugate is disclosed. The conjugates are useful in vaccine production.Type: ApplicationFiled: April 22, 2005Publication date: July 3, 2008Applicant: CHIRON SRLInventor: Cameron John Marshall
-
Publication number: 20080138360Abstract: A vaccine composition for the therapeutic and prophylactic treatment of Hepatitis C, containing as components the Hepatitis C virus structural proteins in certain proportions and having an enhancer effect in the development of the immune response against the Hepatitis C virus. Combined vaccines against pathogenic entities including this vaccine composition are also described.Type: ApplicationFiled: August 29, 2005Publication date: June 12, 2008Inventors: Alexis Lasa Musacchio, Santiago Duenas Carrera, Liz Alvarez-Lajonchere Ponce de Leon, Nelson Acosta Rivero, Gillian Martinez Donato, Maria Guirola Tsibulova, Gretel Sardinas Garcia
-
Publication number: 20080138359Abstract: The present invention relates to Neisserial Lipo-Oligo-Saccharides (LOS) that comprise a tri-saccharide outer core that shows increased binding to the DC-SIGN receptor on dendritic cells, as a result of which the Neisserial LOS's of the invention have increased immunostimulatory activity. The tri-saccharide outer core of the Neiserial LOS's combined with a Lipid A moiety with reduced toxicity is useful as an adjuvant in vaccine preparations.Type: ApplicationFiled: May 11, 2005Publication date: June 12, 2008Inventors: Liana Juliana Josephine Steeghs, Johannes Gerardus Joseph van de Winkel, Peter Andre van der Ley
-
Patent number: 7384639Abstract: The present invention relates to an immunogenic conjugate comprising a carrier molecule coupled to an autoinducer of a Gram negative bacteria The immunogenic conjugate, when combined with a pharmaceutically acceptable carrier, forms a suitable vaccine for mammals to prevent infection by the Gram negative bacteria The immunogenic conjugate is also used to raise and subsequently isolate antibodies or binding portions thereof which are capable of recognizing and binding to the autoinducer. The antibodies or binding portions thereof are utilized in a method of treating infections, a method of inhibiting autoinducer activity, and in diagnostic assays which detect the presence of autoinducers or autoinducer antagonists in fluid or tissue samples.Type: GrantFiled: September 6, 2005Date of Patent: June 10, 2008Assignee: University of RochesterInventors: Andrew S. Kende, Barbara H. Iglewski, Roger Smith, Richard P. Phipps, James P. Pearson
-
Publication number: 20080131455Abstract: The present invention provides antigen delivery compositions and methods of using same to prevent or to treat cancers and other infectious diseases.Type: ApplicationFiled: November 26, 2007Publication date: June 5, 2008Applicant: PDS BIOTECHNOLOGY CORPORATIONInventors: Leaf Huang, Zhengrong Cui, John Dileo, Su-Ji Han, Dileep P. Vangasseri
-
Patent number: 7364740Abstract: Specific genetic deletion are identified in mycobacteria isolates, including variations in the M. tuberculosis genome sequence between isolates, and numerous deletion present in BCG as compared to M. tb. These deletions are used as markers to distinguish between pathogenic and avirulent strains, and as a marker for particular M. tb isolates. Deletions specific to vaccine strains of BCG are useful in determining whether a positive tuberculin skin test is indicative of actual tuberculosis infection. The deleted sequences may be re-introduced into BCG to improve the efficacy of vaccination. Alternatively, the genetic sequence that corresponds to the deletion(s) are deleted from M. bovis or M. tuberculosis to attenuate the pathogenic bacteria.Type: GrantFiled: June 1, 2005Date of Patent: April 29, 2008Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Marcel Behr, Peter Small, Gary Schoolnik, Michael A. Wilson
-
Patent number: 7329409Abstract: The present invention relates to methods and compositions for treatment of microbial infections and for the enhancement of resistance to infection. The invention comprises administration of an effective amount of bacterial lysate compositions for the treatment of pathological conditions of microbial infections. The present invention can also be used to enhance the immune system to prevent infections by the administration of an effective amount of the compositions.Type: GrantFiled: June 30, 2005Date of Patent: February 12, 2008Assignee: Immunology Laboratories, Inc.Inventors: Jiri Pillich, John C. Balcarek
-
Patent number: 7323175Abstract: Immunogenic compositions and subunit vaccines for dental caries are described which comprise peptide subunits of glucan binding protein-B and peptide subunits of glucan binding protein-B in combination with peptide subunits of glucosyltransferase. Methods of provoking an immune response to S. mutans glucan binding protein-B or glucosyltransferase. Methods of immunizing a mammal against dental caries are also described, along with antibodies which bind particular epitopes of glucan binding protein-B or glucosyltransferase.Type: GrantFiled: March 7, 2003Date of Patent: January 29, 2008Assignee: The Forsyth InstituteInventors: Daniel J. Smith, Martin A. Taubman
-
Publication number: 20080019983Abstract: A method of preventing or treating staphylococcal bacterial infection in an individual is disclosed. A vaccine based on a conjugate of PS1 polysaccharide antigen can be used for active protection in individuals who are to be subjected to conditions that place them at immediate risk of developing a bacterial infection, as would be case in the context of a catheterization or a surgical procedure. Alternatively, antibodies raised in response to the antigen can be used to treat or to provide passive protection to individuals. The method can be used in a population of patients at risk for infection by various species of Staphylococcus or various types of Staphylococcus epidermidis.Type: ApplicationFiled: July 20, 2006Publication date: January 24, 2008Applicant: Nabi BiopharmaceuticalsInventors: Ali Fattom, Jawad Sarwar, Zuzana Kossaczka, Kimberly L. Taylor, Sofiane Ennifar
-
Patent number: 7279169Abstract: Mucosal DTPa vaccines, especially intranasal vaccines, comprising (a) a diphtheria antigen, a tetanus antigen and an acellular pertussis antigen, and (b) a detoxified mutant of cholera toxin (CT) or E. coli heat labile toxin (LT). Component (b) acts as a mucosal adjuvant. The acellular pertussis antigen preferably comprises pertussis holotoxin (PT) and filamentous haemagglutinin (FHA) and, optionally, pertactin. The mucosally-delivered combined DTPa formulation is capable of generating a level of protection against B. pertussis infection equivalent to that observed by alum-adjuvanted parenteral administration.Type: GrantFiled: September 28, 2000Date of Patent: October 9, 2007Assignee: Novartis Vaccines and Diagnostics SRLInventors: Rino Rappuoli, Mariagrazia Pizza
-
Patent number: 7258863Abstract: In this application is described a composition, Invaplex, derived from a gram negative bacteria for use in generating an immune response in a subject against one or more heterologous species or strains of gram-negative bacteria.Type: GrantFiled: May 17, 2002Date of Patent: August 21, 2007Assignee: United States of America as represented by the Secretary of the ArmyInventors: Edwin V. Oaks, Kevin R. Turbyfill